Multilateral · Verified
Gavi, the Vaccine Alliance
International vaccine alliance financing routine immunisation and new vaccine introduction in Nepal.
Open positions
No open jobs or tenders right now. Save this organization to be notified when they post.
Recent work
- Nepal: Typhoid Conjugate Vaccine
Gavi prioritised typhoid conjugate vaccines in 2008, as part of the vaccine investment strategy, but did not make a financial commitment due to the absence of a suitable vaccine. Following the WHO prequalification of a newly available typhoid conjugate vaccine at the end of 2017, and the release of SAGE guidance on the use of typhoid conjugate vaccines, Gavi opened a funding window for the vaccine.
Nepal - Nepal: Rotavirus
GAVI’s support for new vaccines presents an opportunity for countries to not only implement vaccines that protect against diseases causing substantial morbidity and/or mortality, but also to build upon the vaccine investments in order to increase immunisation coverage rates, and strengthen routine immunisation services and primary health care systems. Rotavirus vaccine protects children against rotavirus disease and the severe and deadly diarrhoea that it causes in children. WHO recommends that rotavirus vaccination be included in all national immunization programmes, and the use of rotavirus vaccines should be part of a comprehensive strategy to control diarrhoeal diseases. Two oral rotavirus vaccines are currently available for routine infant immunisation with GAVI support: a two-dose schedule and the three-dose schedule vaccine.
Nepal - Nepal: Pentavalent
GAVI’s support for new vaccines presents an opportunity for countries to not only implement vaccines that protect against diseases causing substantial morbidity and/or mortality, but also to build upon the vaccine investments in order to increase immunisation coverage rates, and strengthen routine immunisation services and primary health care systems. The pentavalent vaccine, administered in a three-dose schedule, offers protection against five diseases: diphtheria-tetanus-pertussis (DTP), heptatitis B and Haemophilius influenzae type b. Until 2013, GAVI has helped to introduce the pentavalent in 70 of the 73 GAVI-eligible countries, with the aim of reaching all 73 by the end of 2014. GAVI support for pentavalent vaccine is in line with WHO recommendations, for routine infant immunisation and primarily targeting children under one year of age.
Nepal - Nepal: Pneumococcal Conjugate Vaccines
GAVI’s support for new vaccines presents an opportunity for countries to not only implement vaccines that protect against diseases causing substantial morbidity and/or mortality, but also to build upon the vaccine investments in order to increase immunisation coverage rates, and strengthen routine immunisation services and primary health care systems. Pneumococcal vaccines can protect children from Streptococcus pneumoniae, which is the most common cause of severe pneumonia among children living in the developing world, and can also causes meningitis and sepsis. In line with WHO recommendations, GAVI support for pneumococcal vaccines is for routine infant immunisation. Two pneumococcal conjugate vaccines are currently available with GAVI support: a 10-valent (PCV10) and a 13-valent (PCV13).
Nepal - Nepal: Cholera
Gavi has supported the global oral cholera vaccine stockpile since 2014 Oral cholera vaccine stockpile The global oral cholera vaccine (OCV) stockpile was founded in mid-2013 by five donors. In 2013, the Gavi Board approved support for the stockpile as part of our Vaccine Investment Strategy. Our contribution of over US$ 110 million for the 2014–2018 period aims to increase access to OCV during emergencies and in countries that regularly experience cholera outbreaks.
Nepal - Nepal: Inactivated Polio Vaccine
The Vaccine Alliance supported one of the fastest roll-outs in the history of vaccination: the introduction of at least one dose of IPV into the routine immunisation schedules of Gavi-supported countries, which was achieved in April 2019, less than five years after the initial launch. Countries introducing IPV received a one-time cash grant from Gavi, funded by GPEI, to support some of the additional activity costs related to introducing the new vaccine. These activities may include health worker training, social mobilisation, micro-planning, expansion or rehabilitation of cold chain equipment, printing of materials (such as immunisation cards), technical assistance and modifications to the surveillance systems.
Nepal